Abstract Background: Periprosthetic joint infection is a particularly difficult orthopedic problem, complicating a growing number of revision procedures. Joint debridement and systemic antibiotics are the mainstay of treatment, yet difficulty remains in maintaining a minimum inhibitory concentration of antibiotic at the localized site of infection. Study Aims: This study analyzes the elution characteristics of a 40%bwt calcium phosphate-60%bwt calcium sulfate composite, at varying concentrations of vancomycin. Methods: Four groups of varying concentrations of vancomycin (2.63%bwt, 5.13%, 9.76%, and 17.78%) were mixed with one pack of the composite cement. At designated time intervals up to 28 days, the antibiotic concentration was detected using fluorescence polarization immunoassay and the elution trends compared. Results: The elution rate of each of the four groups decreased over time. At almost all of the intervals, the elution rates of the higher concentration groups were significantly higher than the lower concentration groups (P<0.05). Conclusions: Calcium sulfate reabsorbs over a prolonged period, producing porosity which allows for new bone ingrowth through occupation of osteoprogenitor cells and osteoblasts; while calcium phosphate acts as a long-term osteoconductive matrix. Clinical Relevance: The results of this study suggest that vancomycin can be mixed affectively with a calcium sulfate/ phosphate composite, both maintaining stability and eluting gradually over a clinically relevant period of time.
Introduction
Chronic osteomyelitis is a difficult problem commonly encountered by the orthopedist; the mainstay of treatment is surgical debridement with systemic antibiotic regimens [5, 10, 27] . The 1970s saw the introduction of antibioticimpregnated cements used clinically as a localized delivery system [4, 8] . These antibiotic-cement delivery vehicles maintained a high local concentration and bypassed the problems caused by systemic toxicity and compromised vascularity. Polymethylmethacrylate beads (PMMA) have been advocated as an effective means of antibiotic distribution with numerous studies investigating their efficacy [4, 8, 12 ]. Yet, limitations lie in the exponential elution of the antibiotics in the acute phase with subsequent variable tapering and incomplete elution [16] . In addition, the need for secondary bead removal as PMMA is not biodegradable [8, 12] may also prove troublesome. More recently, biodegradable cement delivery systems have been used [3, 15] avoiding the need for a second surgery to remove material. To date, however, the problem of the resulting bony defects following resorption has not been adequately addressed.
Calcium phosphate (CaP) has been advocated as an affective bone substitute [7] . It maintains mechanical integrity and possesses particularly robust compressive strength [13, 17] after implantation. CaP is known to be immunologically nonreactive and biologically inert [18, 19] , while the close resemblance of the microstructure to the porous nature and mineral content of cancellous bone is a valued biological asset [13] . Several studies have confirmed the efficacy of antibiotic delivery from impregnated CaP is equal to that of PMMA [20, 21] . Calcium sulfate (CaS) has also been extensively used clinically [9, 11] . Biodegradable CaS exhibits an accelerated linear resorption as well as increased bone formation, and is thus, an affective bone substitute in periosteal regions [2] . The swiftly resorbed CaS material is thought to be a biomechanically affective bone substitute that is intrinsically osteocon-ductive and is hypothesized to actively promote osteogenesis [12, [23] [24] [25] [26] 28] .
We sought to investigate the use of a biphasic CaP/CaS composite (CERAMENT TM ) that retains the delivery efficacy for vancomycin of PMMA, but exhibits an improved resorptive profile. The primary aim of this study was to evaluate CERAMENT TM as a vancomycin delivery vehicle in comparison to historical data with CaP alone, by measuring the rates of elution at discrete time intervals. Secondly, we reviewed the biodegradable characteristics of the composite over a 4-week period, again comparing the results to that historically found with the poorly resorbed CaP.
Materials and Methods
The powdered composite was hand mixed with a radiopaque iohexol solution for 1 min until smooth. Four separate batches were made; to each, a different concentration of vancomycin was added. Group I contained 500 μg of vancomycin (2.63% by weight), group II 1,000 μg (5.13%), group III 2,000 μg (9.76%), and group IV 4,000 μg (17.78%) of vancomycin. Each mix was placed in six prefabricated 10×10 mm custom moulds and allowed to harden over 12 h at room temperature. The initial concentration of antibiotic in each group was chosen based on our previous in vitro studies using vancomycin in HA cement; moreover, doses used can be related to current concentrations used in clinical practice [1, 6, 22] . After hardening, each cylinder was placed in a glass scintillation vial with 5 ml of normal saline.
At 3, 6, 12, 24, and 36 h as well as 2, 3, 4, 6, 8, 14, 21, and 28 days, the cylinder was extracted from its vial and rinsed with 1.0 ml 0.9% saline. This solution was collected. The cylinder was then placed in a new vial containing 5.0 ml of 0.9% saline and warmed to 37°C in a water bath. The replaced vials were covered and stored at −20°C until analyzed. Concentrations of vancomycin were detected by using fluorescence polarization immunoassay (Abbott Axsym; Abbott Laboratories, Abbott Park, IL). To calculate the total antibiotic eluted between two time points, 6 ml (the total volume of saline) was multiplied by the measured antibiotic concentration of each sample. This value was then divided by the time interval from the previous time point to develop the elution rate (in milligrams per hour) for each cylinder. The average of the elution rates of the six cylinders was used for each group at each time point.
Results
The elution rate of each of the four groups decreased over time; yet groups IV and III continued to elute clinically significant concentrations of vancomycin throughout the 4-week period, remaining above 0.1 mg at 28 days. Throughout the study, the concentration of groups III and IV never fell below those of groups I and II, regardless of rate of elution.
Yet, the rates of elution differed significantly across all groups. Each group demonstrated an acute fall in elution rate within the first 24 h. At day 6, nearly all composite cylinders collapsed on the surface leaving a smaller residual center. This time point corresponds to the fall in eluant seen in days 4-6 but concentrations returned to their previous levels by day 8 (Fig. 1) .
After 4 weeks, all cylinders had visibly disintegrated in solution. This disintegration occurred slowly over the experimental period regardless of the collapse at 6 days. 
Discussion
The improvement of localized antibiotic delivery has allowed greater advances in the management of complex musculosketelatal surgery. Our study concentrated solely on the properties of vancomycin-impregnated cements. Previous works have noted the poor elution levels particular to this drug in comparison to other antibiotics such as tobramycin. Calcium phosphate products are advocated as carriers for targeted delivery of antibiotics in acute infection, yet, studies have alluded to the poor prolonged release of clinically effective concentrations of vancomycin [3] , in combination with a poor resorption profile. We sought to investigate the elutive properties of a CaP/CaS composite, as well as review the materials resorptive profile. As with many in vitro studies, a weakness of our experimental design is the inability to recreate physiological in vivo conditions and the effects this may have on our outcomes. Indeed, previous in vivo studies using calcium sulfate alone have reported serous wound drainage due to its swift resorptive profile [9] ; this phenomenon would require further in vivo study when in combination with the latently resorbed calcium phosphate. Our laboratories' previous preliminary studies [6] noted the poor elutive characteristics of vancomycin in a pure calcium phosphate carrier; furthermore, at concentrations greater than 4.76%, the handling properties and structural integrity of the cement were notably altered-becoming brittle and losing malleability. At this approximate concentration (5.13%), the elution rate of vancomycin from the composite in this current study was more than ten times higher in the first 6 h and higher at the end of 4 weeks than the pure calcium phosphate product. Previous groups have studied the elutive concentrations of vancomycin for prolonged periods from inert materials and have reported clinically relevant concentrations up to 3 weeks [14] . In this study, the 4-week time point was included to detect latent elutive concentrations from the resorbed composite.
Simplex and Palacos have shown variable elution profiles with vancomycin [1, 22] , where PMMA was impregnated with 5.2 wt.% antibiotic and demonstrated inconsistent kinetics within 36 h. In comparison, results from our study demonstrated a prolonged elution of clinically significant concentrations at a similar dose (5.13%) for a minimum of 21 days.
Although we noted a marked reduction in vancomycin release in the initial hours, there remained a clinically significant residual concentration. The rate may be 0.05-0.1 mg/h at the plateau, much lower than the initial release, but this continuous elution may well be important to final remediation of the infection locally. Further work is required to elucidate whether the resorbable nature of the composite material will facilitate protracted antibiotic release in vivo.
The attributes of CERAMENT TM may go further than the apparent superior ability to act as an effective vancomycin vehicle. Indeed, the 40% calcium phosphate and 60% calcium sulfate hemihydrate complex does not fully interact in solution. Instead, when calcium sulfate hemihydrate comes in contact with the iohexol solution, it is ionized and re-crystallizes into calcium sulfate dihydrate.
The needle-shaped structure enables the crystals to interlock and form a stable, porous matrix. The calcium phosphate does not bond directly, but is instead evenly spread throughout the matrix. Consequently, in vivo, the calcium sulfate dihydrate is reabsorbed making the material more porous and thereby allowing bone ingrowth, while the CaP remains stable in the matrix during the ingrowth process. These characteristics require further in vivo investigation, reviewing the osteogenic capacity of the composite. In addition, the non-exothermic nature of the composite at creation further broadens its clinical application. The historic inability to use heat-sensitive antibiotics such as metronidazole and doxycycline with bone cements may be overcome with this inert composite. These qualities would be of particular interest in comparison with currently available PMMA and hydroxyapatite cements.
Ultimately, our study suggests a clinically relevant alternative to the current cement composites on the market. Elution rates from this composite are improved compared to those found with hydroxyapatite by our own group (Table 1) . Clinically, the composite application must be investigated in settings of poor vascularity. Bone compromised by osteomyelitis is known to have poor vascularity. Many of the beneficial properties of calcium sulfate as a substitute rely heavily on angiogenesis and localized neovascularisation to promote osteoid deposition. To this end, further investigation is required to determine the efficacy of this composite's ability to prevent as well as treat infection in an established in vivo model of osteomyelitis.
In summary, any improvement in maintaining antibiotic levels in the setting of osteomyelitis is an invaluable resource to the orthopedist. The combined characteristics of the calcium phosphate-calcium sulfate composite have produced promising results in this study. The in vitro elution profile of the composite suggests that it could be more effective as an antibiotic delivery vehicle as calcium phosphate alone. Further in vivo studies are required to fully investigate its application clinically.
